Your browser doesn't support javascript.
loading
PPARγ Agonists: Emergent Therapy in Endometriosis.
Vallée, Alexandre; Vallée, Jean-Noël; Le Blanche, Alain; Lecarpentier, Yves.
Afiliação
  • Vallée A; Department of Clinical Research and Innovation (DRCI), Foch Hospital, 92150 Suresnes, France.
  • Vallée JN; Centre Hospitalier Universitaire (CHU) Amiens Picardie, Université Picardie Jules Verne (UPJV), 80000 Amiens, France.
  • Le Blanche A; DACTIM-Mis, Laboratoire de Mathématiques et Applications (LMA), UMR CNRS 7348, Université de Poitiers, 86000 Poitiers, France.
  • Lecarpentier Y; Laboratoire CeRSM (EA-2931), UPL, Université Paris Nanterre, F92000 Nanterre, France.
Pharmaceuticals (Basel) ; 14(6)2021 Jun 06.
Article em En | MEDLINE | ID: mdl-34204039
Endometriosis is one of the major gynecological diseases of reproductive-age women. This disease is characterized by the presence of glands and stroma outside the uterine cavity. Several studies have shown the major role of inflammation, angiogenesis, adhesion and invasion, and apoptosis in endometriotic lesions. Nevertheless, the mechanisms underlying endometriotic mechanisms still remain unclear and therapies are not currently efficient. The introduction of new agents can be effective by improving the condition of patients. PPARγ ligands can directly modulate these pathways in endometriosis. However, data in humans remain low. Thus, the purpose of this review is to summarize the potential actions of PPARγ agonists in endometriosis by acting on inflammation, angiogenesis, invasion, adhesion, and apoptosis.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article